Skip to main content

Drug Interactions between pemivibart and sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

SARS-CoV-2 (COVID-19) mRNA-1273 bivalent vaccine pemivibart

Applies to: sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine and pemivibart

If you have recently been vaccinated with SARS-CoV-2 (COVID-19) mRNA-1273 bivalent vaccine, you should not receive pemivibart for at least 14 days. Treatment with pemivibart may reduce the effectiveness of SARS-CoV-2 (COVID-19) mRNA-1273 bivalent vaccine as it could interfere with the vaccine's ability to produce an adequate immune response to the COVID-19 virus. However, you should continue to receive SARS-CoV-2 (COVID-19) mRNA-1273 bivalent vaccine as indicated by local guidelines based on your condition. Pemivibart should not be used as a replacement for SARS-CoV-2 (COVID-19) mRNA-1273 bivalent vaccine. Talk to your doctor or other healthcare providers if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer